

Research

Open Access

## Pathogenic infection of *Macaca nemestrina* with a CCR5-tropic subtype-C simian-human immunodeficiency virus

On Ho<sup>1</sup>, Kay Larsen<sup>2</sup>, Patricia Polacino<sup>2</sup>, Yun Li<sup>1</sup>, David Anderson<sup>2</sup>, Ruijiang Song<sup>3,4,5</sup>, Ruth M Ruprecht<sup>3,4</sup> and Shiu-Lok Hu\*<sup>1,2</sup>

Address: <sup>1</sup>Department of Pharmaceutics, University of Washington, Box 357610, Seattle, Washington 98195, USA, <sup>2</sup>Washington National Primate Research Center, University of Washington, 3000 Western Avenue, Seattle, WA 98121, USA, <sup>3</sup>Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA, <sup>4</sup>Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA and <sup>5</sup>Aaron Diamond AIDS Research Center, 455 1st Ave, 7th Floor, New York, NY 10016, USA

Email: On Ho - onh@bart.rprc.washington.edu; Kay Larsen - kayl@bart.rprc.washington.edu; Patricia Polacino - patf@bart.rprc.washington.edu; Yun Li - yunli@bart.rprc.washington.edu; David Anderson - davea@bart.rprc.washington.edu; Ruijiang Song - rsong@adarc.org; Ruth M Ruprecht - ruth\_ruprecht@dfci.harvard.edu; Shiu-Lok Hu\* - hus@bart.rprc.washington.edu

\* Corresponding author

Published: 14 July 2009

Received: 28 April 2009

Retrovirology 2009, 6:65 doi:10.1186/1742-4690-6-65

Accepted: 14 July 2009

This article is available from: <http://www.retrovirology.com/content/6/1/65>

© 2009 Ho et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** Although pig-tailed macaques (*Macaca nemestrina*) have been used in AIDS research for years, less is known about the early immunopathogenic events in this species, as compared to rhesus macaques (*Macaca mulatta*). Similarly, the events in early infection are well-characterized for simian immunodeficiency viruses (SIV), but less so for chimeric simian-human immunodeficiency viruses (SHIV), although the latter have been widely used in HIV vaccine studies. Here, we report the consequences of intrarectal infection with a CCR5-tropic clade C SHIV-1157ipd3N4 in pig-tailed macaques.

**Results:** Plasma and cell-associated virus was detectable in peripheral blood and intestinal tissues of all four pig-tailed macaques following intrarectal inoculation with SHIV-1157ipd3N4. We also observed a rapid and irreversible loss of CD4<sup>+</sup> T cells at multiple mucosal sites, resulting in a marked decrease of CD4:CD8 T cell ratios 0.5–4 weeks after inoculation. This depletion targeted subsets of CD4<sup>+</sup> T cells expressing the CCR5 coreceptor and having a CD28-CD95<sup>+</sup> effector memory phenotype, consistent with the R5-tropism of SHIV-1157ipd3N4. All three animals that were studied beyond the acute phase seroconverted as early as week 4, with two developing cross-clade neutralizing antibody responses by week 24. These two animals also demonstrated persistent plasma viremia for >48 weeks. One of these animals developed AIDS, as shown by peripheral blood CD4<sup>+</sup> T-cell depletion starting at 20 weeks post inoculation.

**Conclusion:** These findings indicate that SHIV-1157ipd3N4-induced pathogenesis in pig-tailed macaques followed a similar course as SIV-infected rhesus macaques. Thus, R5 SHIV-C-infection of pig-tailed macaques could provide a useful and relevant model for AIDS vaccine and pathogenesis research.

## Background

The research of AIDS pathogenesis has been facilitated by the use of Asian macaques known to develop AIDS-like diseases from lentivirus infection, including rhesus (*M. mulatta*), cynomolgus (*M. fascicularis*), and pig-tailed (*M. nemestrina*) macaques [1-11]. Studies in rhesus macaques have provided extensive insight into the biology of disease-susceptible animals to advance ongoing efforts towards developing an effective human AIDS vaccine. On the other hand, much less is known about the early events after lentiviral infection in other macaque species, including pig-tailed macaques.

The species/subspecies of macaques used in a study can be a significant determinant of viral infectivity and disease susceptibility. For example, in a comparative study of Asian macaques infected intravenously with simian immunodeficiency virus (SIV) or simian-human immunodeficiency virus (SHIV) strains, SIVmac251 or SHIV89.6P, Reimann et al. found lower plasma viral loads, higher levels of peripheral CD4<sup>+</sup> T cells, and higher survival rates in cynomolgus and Chinese rhesus, compared to similarly infected Indian rhesus [12]. Interestingly, ten Haaf et al. reported contrasting findings in cynomolgus vs. Indian rhesus infected intravenously or via select mucosal routes [13]. Their study showed that while cynomolgus macaques had lower steady-state viral loads after SIV infection, there was no such difference after SHIV89.6P infection. Consistent with the Reimann et al. report above, Ling et al. also showed a differential response to lentiviral infection at the subspecies level. Compared to their Indian counterparts, Chinese rhesus infected with SIVmac239 had lower plasma viral loads in acute infection, maintained lower setpoint plasma viremia, and experienced less severe depletion of intestinal CD4<sup>+</sup> effector cells, all of which resulted in better clinical outcomes [14]. However, Burdo et al. found that serial passage of SIVmac128 in Chinese rhesus resulted in increased steady-state viral loads as compared to animals infected with the virus derived from Indian monkeys, implying that host adaptation plays an important role in viral fitness and pathogenicity [15].

Taken together, these findings suggest that the efforts to develop an AIDS vaccine may be well served by examining a diverse range of antiviral responses and disease susceptibilities in different animal models. Pig-tailed macaques are of particular interest for several reasons. First, despite sharing a common ancestor, pig-tailed macaques are more distantly related to cynomolgus and rhesus macaques than the latter species are to each other [16,17]. This evolutionary distance may have genetic implications affecting components of the adaptive immune response, including T-cell receptor diversity and major histocompatibility complex (MHC) molecules [18,19]. Second,

pig-tailed macaques are defective in a restriction factor TRIM5 $\alpha$  [20] used by rhesus macaques to inhibit replication by certain retroviruses, such as HIV-1 [21]. Pig-tailed macaques have previously been shown to be susceptible to infection by HIV-1 [22,23] and recently, by simian-tropic (st)HIV-1 strains [24]. Third, evidence exists indicating that pig-tails are more susceptible to lentivirus-induced disease. In a comparative study of pig-tailed and rhesus macaques infected with SHIV<sub>SF162P47</sub>, Polacino et al. found higher peak and setpoint viral loads in pig-tailed macaques despite similar infectivity between the two species, demonstrating that pig-tails were less able to control infection [25]. This finding was consistent with an early report by Rosenberg et al., who found that SIV<sub>PBJ-14</sub>-infected pig-tailed macaques were more susceptible to death resulting from gastrointestinal distress than their rhesus counterparts [26]. Similarly, other studies have documented persistent infection, CD4<sup>+</sup> T cell depletion, and/or development of AIDS-like diseases in pig-tails, but not rhesus, infected with HIV-2 primary isolates [27-29]. Thus, based on their increased susceptibility to HIV infection and to lentivirus-induced disease, compared to rhesus, pig-tailed macaques may be a useful animal model for addressing the diverse responses to HIV-1 infection in humans.

Elucidation of the immunopathogenic events in mucosa-associated lymphoid tissue (MALT) has been a major advance in AIDS research in the last ten years [30,31]. Dramatic and irreversible depletion of CD4<sup>+</sup> T cells at multiple mucosal sites occurs early after SIV infection [32-42]. Furthermore, the virus specifically targets CCR5<sup>+</sup> and activated memory CD4<sup>+</sup> T-cells [35,37,40-45] comprising the majority of total lymphocytes found in MALT, especially in the intestine, the largest immunologic organ in the body [46,47]. In contrast, these subsets represent small numbers of circulating CD4<sup>+</sup> lymphocytes in blood, lymph nodes, and other secondary lymphoid tissues. Consequently, depletion of CD4<sup>+</sup> T cells in these tissues is not as dramatic as in the mucosal compartment during acute infection [32,35,37-39,42,48]. Thus, monitoring mucosal CD4<sup>+</sup> T cells may provide important insight into lentivirus-induced immunopathogenesis. However, compared to the extensive knowledge accumulated from rhesus studies, less is known about mucosal pathogenic events in pig-tailed macaques during early infection.

The rapid depletion of CD4<sup>+</sup> T cells observed in the MALT of SIV-infected macaques contrasts with the depletion observed in peripheral blood of macaques infected with the first-generation of SHIVs, such as SHIV-HXBc2 and SHIV89.6P. This discrepancy most likely reflects the CXCR4-tropism of these SHIVs vs. the CCR5-tropism of SIV [49,50]. As most of the transmitted viruses in sexual and maternal-infant HIV-1 infection are CCR5-tropic, the

use of R5 SHIVs may be more biologically relevant in pre-clinical vaccine studies [51]. Furthermore, currently available SHIVs are predominantly derived from subtype B isolates of HIV-1 [52-57], whereas the majority of global infections results from subtype C virus transmission [51]. Recently, Song et al. reported the construction of a CCR5-tropic subtype C SHIV-1157ipd3N4 (also referred to as SHIV-C for short), which has been shown to be highly replication-competent and mucosally transmissible in Indian- and Chinese-origin rhesus macaques [58]. Three of five rhesus infected with parental versions of SHIV-1157ipd3N4 progressed to AIDS within 2–5 years post-exposure [59]. Two of the 13 rhesus monkeys infected with SHIV-1157ipd3N4 also progressed to AIDS within 80–100 weeks (Chenine et al., unpublished data). This pathogenic R5-tropic SHIV-C may therefore represent an important tool for pathogenesis study of primate lentiviruses and preclinical evaluation of candidate HIV vaccines. In the present study, we evaluated the infectivity and pathogenicity of SHIV-1157ipd3N4 in pig-tailed macaques to determine its potential role as an alternative challenge model in future AIDS vaccine studies.

## Results and discussion

### SHIV-1157ipd3N4 infection in pig-tailed macaques

All four pig-tailed macaques inoculated intrarectally with SHIV-1157ipd3N4 were susceptible to infection and showed peak plasma viral loads averaging  $7.6 \pm 5.8 \times 10^6$  viral RNA copies/ml by 2 weeks post-inoculation (p.i.) (Fig. 1A). At this time, macaque M04123 died due to complications of the intestinal biopsy procedure. Its terminal plasma viral load was  $1.1 \times 10^7$  copies/ml. Plasma viremia persisted in two of the three remaining animals, with levels ranging from  $7 \times 10^3$  to  $2 \times 10^5$  copies/ml of plasma. In contrast, virus replication was controlled below the level of quantification (100 copies/ml) in macaque J02185 by week 6 following inoculation. Similar kinetics of infectivity were observed in peripheral blood and mucosal mononuclear cells (PBMC and MMC), where mean viral loads peaked by 1.5–2 weeks p.i. ( $1.5 \pm 0.6 \times 10^3$  and  $0.3 \pm 0.2 \times 10^3$  copies/ $\mu$ g of DNA, respectively; Fig. 1B–C). After the initial peak of viremia, viral load in PBMC persisted in all three macaques within a range of 21 to 915 copies/ $\mu$ g of DNA (Fig. 1B). In the duodenum, viral load in MMC was below detection by week 6 p.i., except in macaque K03135 that showed elevated levels of virus between weeks 10 and 16 p.i. (Fig. 1C).

The fact that all four pig-tailed macaques became infected after inoculation with SHIV-1157ipd3N4 confirmed the susceptibility of this species to infection by this virus, which was propagated and studied only in rhesus monkeys [58]. Peak viral loads from the four infected pig-tailed macaques approached the lower range reported for Indian rhesus, and within the range for Chinese rhesus


[58] (Fig. 1A). Plasma virus also peaked at the same time in both species (2 weeks p.i.). Viremia persisted in 2/3 pig-tails during the year-long study, similar to results reported for rhesus monkeys (3/5 and 3/8, respectively, for Chinese and Indian rhesus) [58] (Fig. 1A).

### Early and severe SHIV-1157ipd3N4-induced mucosal immunopathogenesis


To examine the effect of R5 SHIV-C infection on mucosal CD4<sup>+</sup> T cells, especially during the early stages after virus inoculation, we performed a longitudinal analysis of CD3<sup>+</sup>CD4<sup>+</sup> T lymphocytes by flow cytometry. As early as 2 weeks p.i., CD3<sup>+</sup>CD4<sup>+</sup> T cells in the duodenum had significantly decreased from a pre-inoculation level of 38.3% to 13.3% (standard deviation of 5.2% and 15%, respectively) (Fig. 2A). By 3–4 weeks p.i., only  $2.2 \pm 1\%$  of CD3<sup>+</sup>CD4<sup>+</sup> T lymphocytes were detectable in the duodenum of three animals, reflecting a dramatic depletion of 92–97% of the total CD4<sup>+</sup> T-cell population in the duodenal mucosa. Notably, despite the nearly undetectable plasma and MMC viral load in macaque J02185 by 6 weeks p.i., the ability to control virus replication did not appear to lessen the depletion of intestinal CD4<sup>+</sup> T cells in this animal (Fig. 1A and 1C; and Fig. 2A). In fact, J02185 showed the highest degree of CD4<sup>+</sup> T-cell depletion in the duodenum at 97% by 4 weeks p.i. For all three animals, the percentages of CD3<sup>+</sup>CD4<sup>+</sup> T cells in the duodenum slightly recovered over the course of 24 weeks to levels that did not exceed  $11.3 \pm 2.5\%$ , or approximately 28% of pre-inoculation levels (Fig. 2A).

The severe loss of CD3<sup>+</sup>CD4<sup>+</sup> T cells was also found in other mucosal tissues, including the colon and the lung, the latter accessible by bronchoalveolar lavage (BAL) sampling (Fig. 2B). Similar to the duodenum, depletion of CD4<sup>+</sup> T cells was not observed in the colon at week 1 p.i. in two macaques (data not shown). By week 4 p.i., CD4<sup>+</sup> T-cell levels had decreased from 43.4% to 9.2%, or 79% from pre-existing levels in macaque L03165. The elimination of CD4<sup>+</sup> T lymphocytes was more severe and rapid in lung mucosa, where CD3<sup>+</sup>CD4<sup>+</sup> T cells were undetectable by 3 days p.i. In fact, BAL CD4<sup>+</sup> T cells remained at undetectable or nearly undetectable levels for 1–2 weeks after virus inoculation in two macaques (Fig. 2B; and data not shown). However, in at least one macaque (L03165), the percentage of CD3<sup>+</sup>CD4<sup>+</sup> T cells in the BAL returned to pre-inoculation levels by week 20 p.i. (Fig. 2B).

As a result of the profound depletion of CD4<sup>+</sup> T cells in the mucosal tissues, we observed a striking decrease of CD4:CD8 T cell ratios during acute infection (Fig. 2C). By 2–4 weeks p.i., the T-cell ratios in the duodenum had decreased nearly 23-fold, from a pre-inoculation range of 0.47–0.74 to a post-inoculation range of 0.016–0.037. The decrease in the duodenal T-cell ratios largely persisted



**Figure 1**  
**Plasma and cell-associated viral loads in pig-tailed macaques infected with SHIV-1157ipd3N4.** Viral RNA loads were measured in plasma (A), and proviral cDNA loads in total mononuclear cells isolated from peripheral blood (B) and duodenum (C). To distinguish data points in the early stages of infection, a scale break (//) corresponding to week 8 after inoculation was inserted into the x-axis (same for subsequent figures).



**Figure 2**  
**Mucosal CD4+ T-cell depletion due to SHIV-1157ipd3N4 infection.** (A) Total lymphocytes isolated from duodenal biopsies from infected pig-tailed macaques were analyzed by flow cytometry for CD3+CD4+ T cells. CD4+ T-cell percentages were obtained by gating on CD3+ T cells and then lymphocytes. (B) Histogram plots showing a comparison of CD4+ T-cell percentages in mucosal tissues of macaque L03165. Duodenal and colonic biopsies, and BAL samples, were taken concurrently at the specified timepoints pre- and post-inoculation. (C) CD4:CD8 ratios in the duodenum were generated by using the percentages of total CD4+ and CD8+ T cells.

throughout the course of infection, with recovery in CD3<sup>+</sup>CD4<sup>+</sup> T-cell levels resulting in only minimal increases in the CD4:CD8 ratios, which did not exceed 0.18. In macaque L03165, the massive elimination of BAL CD4<sup>+</sup> T cells as early as 3 days p.i. resulted in a marked decrease of CD4:CD8 T-cell ratios up to 2 weeks p.i., dropping from a pre-inoculation ratio of 0.43 to a range of 0–0.003 after infection (data not shown).

To our knowledge, this is the first report of a prospective analysis of the immunopathogenesis in multiple mucosal compartments during infection with a R5 SHIV in pig-tailed macaques. Chen et al. found that pig-tailed macaques infected with a R5-tropic clade C SHIV<sub>CHN19P4</sub> were significantly depleted of jejunal CD4<sup>+</sup> T cells at 2 weeks p.i., with no remarkable change in immune activation or proliferation of CD4<sup>+</sup> gut lymphocytes, as measured by CD25 and Ki67 staining, respectively [60,61]. Chase et al. reported that ileal CCR5<sup>+</sup>CD4<sup>+</sup> T cells of pig-tails inoculated with an immunosuppressive viral strain SIV/ΔB670 together with a macrophage-tropic molecular clone SIV/17E-Fr dropped from average uninfected levels of 44% to 8% by 2 weeks p.i. [62]. A significant decrease in CD25<sup>hi</sup> cells and an increase in Ki67<sup>+</sup> cells were also observed in CD4<sup>+</sup> gut lymphocytes from the SIV-infected animals [62]. Our data confirm and extend these previous findings that gut immunopathogenesis is a hallmark of early R5-tropic SIV/SHIV infection in pig-tailed macaques.


The results reported here also indicate that R5 SHIV-C-induced mucosal pathogenesis in pig-tails followed a similar course as described in SIV-infected rhesus. These studies demonstrated profound CD4<sup>+</sup> T-cell losses, nearly complete in some cases, by days 10–21 after infection [32–42]. There is no discernable difference in the depletion of CD4<sup>+</sup> T lymphocytes within intestinal and lung mucosa in pig-tails, with regard to the kinetics or severity of the depletion, compared to these previous reports in rhesus. Notably, the elimination of mucosal CD4<sup>+</sup> T cells in pig-tailed macaques was often followed by the partial or limited return of these populations over the course of the study period (Fig. 2A–B). In fact, the partial recovery of CD4<sup>+</sup> T cells in the gut of SIVmac251-infected rhesus macaques has been documented by Veazey et al., who showed intestinal CD3<sup>+</sup>CD4<sup>+</sup> T cells increased up to 20% by week 5 p.i. in a few infected animals [40]. Similarly, Okoye et al. reported that BAL CD4<sup>+</sup> T-cell levels from SIVmac239-infected rhesus initially recovered after early depletion up to approximately 14 weeks p.i., then decreased progressively thereafter [63]. The mechanism underlying the recovery of mucosal CD4<sup>+</sup> T cells after acute infection remains to be defined, although there is evidence identifying the majority of repopulating intestinal CD4<sup>+</sup> T cells as naïve [40,42]. While the rebound of mucosal CD4<sup>+</sup> T cells appeared to be partial and/or tran-

sient, depletion of this cell population in early SHIV infection was sustained during the course of infection (Fig. 2A–B). Moreover, peak infection of intestinal mononuclear cells at 1.5–2 weeks p.i. coincided with the onset of CD4<sup>+</sup> T-cell depletion, consistent with previous findings [33,35,38,39,44,46,61,64,65] (Figs. 1C and 2A). Thus, the availability of target cells is a critical determinant of mucosal immunopathogenesis.

#### **Acute SHIV-1157ipd3N4 infection results in specific elimination of mucosal CCR5<sup>+</sup> and effector memory CD4<sup>+</sup> T lymphocytes**

The selective targeting of CCR5<sup>+</sup> and effector memory CD4<sup>+</sup> T cells in the mucosal compartment has been well documented in SIV-infected rhesus macaques [35,37,40–45], yet less is known about these subsets in pig-tailed macaques during infection. We therefore examined mucosal CD4<sup>+</sup> T cells for CCR5 and effector memory markers. By 2–3 weeks p.i., we found that a large decrease of duodenal CD4<sup>+</sup>CCR5<sup>+</sup> T cells had occurred in all four SHIV-1157ipd3N4-infected pig-tailed macaques. Percentages of CCR5-expressing T cells dropped from 79% in uninfected animals to 13% by 2–3 weeks p.i. (standard deviation of 9% and 10.5%, respectively), or approximately a decrease of  $82 \pm 15.8\%$  from pre-inoculation levels (Fig. 3A). After the initial early depletion, the percentages of CD4<sup>+</sup>CCR5<sup>+</sup> T cells in three macaques showed fluctuations before increasing during the later stages of the study period. By 20–24 weeks p.i., the percentages of CD4<sup>+</sup>CCR5<sup>+</sup> T cells had recovered to  $98 \pm 26\%$  of pre-inoculation numbers (Fig. 3A). It is unknown whether this level of recovery was transient, based on a singular measurement after week 12, or influenced by the small CD4<sup>+</sup> T-cell population remaining ( $8.8 \pm 4.2\%$ ) at 20–24 weeks p.i. Yet, the fact that this increase occurred in all three animals indicates the recovery of CD4<sup>+</sup>CCR5<sup>+</sup> T cells during this time was consistent (Fig. 3A).

A substantial reduction of CD4<sup>+</sup> effector memory T cells (T<sub>EM</sub>), identified by their CD28-CD95<sup>+</sup> phenotype, was also seen in the duodenum of all four infected pig-tails. By 2–4 weeks p.i., these numbers fell from 33.2% to 0% in J02185; 75.6% to 3.6% in K03135; 22.2% to 8.6% in L03165; and 21.9% to 7.4% in M04123 (Fig. 3B). On average, CD4<sup>+</sup>T<sub>EM</sub> dropped from 38.2% to 4.9% (standard deviation of 25.5% and 3.9%, respectively), reflecting an  $80.7 \pm 19.7\%$  decrease of pre-existing populations. CD4<sup>+</sup>T<sub>EM</sub> cells were undetectable by flow cytometry at 2 weeks p.i. in macaque J02185, the same animal whose CD4<sup>+</sup> T cells were 97% depleted by week 4 p.i. (Figs. 2A and 3B). By 20–24 weeks p.i., the numbers of CD4<sup>+</sup>T<sub>EM</sub> in all three macaques followed beyond the acute phase had recovered to  $62.4 \pm 11.3\%$  of their pre-inoculation levels, despite only a 28% recovery in total CD4<sup>+</sup> T cells (Figs. 2A and 3B). The coincident increase of central memory CD4<sup>+</sup>



**Figure 3**  
**Selective loss of intestinal CCR5<sup>+</sup> and effector memory CD4<sup>+</sup> T cells during early R5 SHIV-C infection.** Total lymphocytes isolated from duodenal biopsies from SHIV-1157ipd3N4-infected pig-tailed macaques were analyzed by flow cytometry for CD4<sup>+</sup> T-cell subsets based on expression of (A) CCR5<sup>+</sup> (B) CD28<sup>-</sup>CD95<sup>+</sup> (T<sub>EM</sub>) and (C) CD28<sup>+</sup>CD95<sup>+</sup> (T<sub>CM</sub>). Percentages of subsets were obtained by gating on CD3<sup>+</sup> T cells, lymphocytes, and then CD4<sup>+</sup> T cells.

T cells ( $T_{CM}$ ) beginning at 2 weeks p.i., when the effector memory subset was profoundly depleted (Fig. 3C), suggests a homeostatic mechanism whereby the  $T_{EM}$  are derived from the proliferation and differentiation of the  $T_{CM}$  population [63]. Thereafter,  $T_{CM}$  levels reached a plateau in all three animals until week 12 p.i., at which time this cell population decreased in K03135.

Our results indicate that SHIV-1157ipd3N4 induced a similar immunopathogenesis in pig-tails as SIV in rhesus, based on the R5-tropism of both viruses. Rhesus macaques showed a dramatic decline of mucosal  $CD4^+$  T cells with a  $CCR5^+$  memory phenotype at 11–28 days following infection [35,37,40–45]. The specific targeting of mucosal  $CCR5$  and effector memory  $CD4^+$  T cell subsets is consistent with the elevated levels of  $CCR5$  on activated memory T cells [32,46,47], and the predominance of an activated/memory phenotype in mucosal tissue [30,31]. In fact, rhesus studies have reported that large numbers of  $CCR5^+$  target cells reside at mucosal sites, including the gut and lung, where approximately 50–90% of  $CD4^+$  T cells express  $CCR5$  [30–32,35,40,41,44,66]. We found comparable levels of  $CCR5^+CD4^+$  T cells in our analysis of mucosal tissues from uninfected pig-tailed macaques, including the duodenum ( $79 \pm 9\%$ ), colon ( $63 \pm 10\%$ ), and BAL ( $98 \pm 0.4\%$ ), the latter reported for two of four animals. Therefore, as reported in SIV-infected rhesus, the mucosa provides a critical reservoir of  $CD4^+$  target cells for R5-specific SHIV-C infection in pig-tails as demonstrated by the sharp decrease of  $CCR5^+$  and  $T_{EM}$  cells by 2 weeks p.i (Fig. 3A–B).

The basis for the apparent increase of intestinal  $CCR5^+$  and  $T_{EM}$  cells after initial depletion (Fig. 3A–B) is not well understood. As the percentages of the subsets are based on total  $CD4^+$  T numbers, it follows that proportional increases in  $CCR5^+$  and  $T_{EM}$  cells concurrent with severe  $CD4^+$  T-cell losses during acute and chronic infection (Fig. 2A) may result in the apparent "recovery" of the subset populations [42]. Further, Veazey et al. observed at 2 weeks p.i. that more than 50% of the residual intestinal  $CD4^+$  T cells in a few SIV-infected rhesus were  $CCR5^+$  and naive ( $CD45RA^{HI}$ ) [40]. At 4–6 months p.i. most residual  $CD4^+$  T cells in the gut were naive, but lacked  $CCR5$  expression [40]. Thus, while it is possible that the "recovery" of  $CCR5^+$  and memory subsets may represent actual residual cells which remained and expanded, these populations may also be derived from naive cells newly formed and recruited to the mucosa early after infection [40,42].

#### **Loss of specific $CD4^+$ T cell subsets during acute SHIV-1157ipd3N4 infection also occurs in peripheral blood**


A comparatively smaller, but detectable, decrease in the absolute number of  $CD3^+CD4^+$  T-cells was also observed in peripheral blood at early timepoints following virus

inoculation, dropping  $12 \pm 29\%$  and  $44 \pm 19\%$  from pre-existing levels, at 2 and 4 weeks p.i., respectively (Fig. 4A). Thereafter, absolute peripheral  $CD4^+$  T-cell counts remained relatively stable in two of three animals, ranging from 519 to 1,257 cells/ $\mu$ l for the duration of the study period.  $CD4^+$  T cell numbers dropped below 200 cells/ $\mu$ l in macaque K03135 at week 20 p.i. and have since shown a progressive decline at all subsequent timepoints, indicating progression to AIDS. Between weeks 10–16 p.i., animal K03135 showed a pronounced increase in viral load in the duodenum (Fig. 1C). The basis for this increase is not clear, but may reflect immune escape or local reactivation of latent viruses [67–69]. There were also no overt clinical signs that correlated with this distinct viral peak. However, it is notable that this increase in MMC viral load occurred at the same time as the increase in plasma viral load (Fig. 1A), and just before the decline of  $CD4^+$  T-cells in peripheral blood (Fig. 4A).


We also observed decreases in the absolute counts of  $CCR5^+$  and  $CD28-CD95^+$  subsets in peripheral blood  $CD4^+$  T cells from all four pig-tailed macaques in early R5 SHIV-C infection (Fig. 4B–C). By 2–3 weeks p.i.,  $CCR5^+$  expressing T cells dropped from 15.2 to 6.2 cells/ $\mu$ l (standard deviation of 4.1 and 2.3 cells/ $\mu$ l, respectively), or  $56.9 \pm 21.6\%$  from pre-challenge levels (Fig. 4B). Similarly,  $CD4^+ T_{EM}$  fell from 32.9 to 13.1 cells/ $\mu$ l (standard deviation of 12.5 and 4.4 cells/ $\mu$ l, respectively), reflecting a loss of  $58 \pm 13.7\%$  in this population (Fig. 4C). However, compared to the duodenum, substantially lower levels of these subsets were found in the peripheral blood of uninfected pig-tails (for  $CCR5^+$ ,  $79 \pm 9\%$  vs.  $2.8 \pm 0.3\%$ ; for  $CD28-CD95^+$ ,  $38.2 \pm 25.5\%$  vs.  $4.5 \pm 1.7\%$ ) (Fig. 3A–B; and data not shown). Similarly low levels of peripheral blood  $CD4^+$  T cells expressing  $CCR5$  and having an effector memory phenotype (approximately 3–16%) have been reported in rhesus macaques [30,31,35,40,41,66]. Thus, consistent with previous findings in rhesus, the small numbers of pre-existing peripheral  $CCR5^+$  and  $T_{EM}$  cells in pig-tailed macaques precluded dramatic changes to the total absolute  $CD4^+$  T-cell count, despite substantial losses to the population subsets due to SHIV-C infection (Fig. 4).

Macaque L03165 died under anesthesia during a mucosal sampling procedure at 48 weeks p.i. This animal had shown persistent viremia, but otherwise normal peripheral  $CD4^+$  T-cell levels (Figs. 1A and 4A). Necropsy revealed a near-occlusive pulmonary arterial thrombus. The clinical history of L03165 indicated a dramatically reduced platelet count and a moderate decrease in the albumin:globulin protein ratio (Fig. 5A–B). A reduced platelet count has also been documented in macaque K03135, the only animal to have developed peripheral  $CD4^+$  T-cell lymphopenia (Fig. 4A; and Fig. 5A and 5C).





**Figure 4**  
**Selective loss of CD4<sup>+</sup> T-cell subsets in the peripheral blood of R5 SHIV-C-infected pig-tailed macaques.** Flow cytometric evaluation of (A) total CD4<sup>+</sup> T cells and subsets based on expression of (B) CCR5<sup>+</sup> and (C) CD28-CD95<sup>+</sup> (T<sub>EM</sub>) was done using whole blood (for total CD4<sup>+</sup> T cells) or total lymphocytes isolated from peripheral blood (for subsets). Analysis was performed by gating first on lymphocytes and then CD3<sup>+</sup>CD4<sup>+</sup> T cells. Total absolute counts of CD4<sup>+</sup> T cells were calculated by multiplying the percentage of CD3<sup>+</sup>CD4<sup>+</sup> T cells by the number of total lymphocytes/ml from complete blood count (CBC) analysis. Further multiplication of the percentage of cells expressing CCR5<sup>+</sup> or CD28-CD95<sup>+</sup> was done to calculate the absolute counts of the subsets. The dashed line in (A) indicates 200 cells/μl, the threshold level defining human AIDS.



**Figure 5**  
**Thrombocytopenia and hematological changes in SHIV-C-infected pig-tailed macaques.** Blood samples were collected at the indicated times following SHIV-C inoculation and analyzed for (A) platelet counts, (B) albumin:globulin ratios, and (C) correlation between platelet and peripheral CD4<sup>+</sup> T-cell counts. Note the different scales along the x- and y-axes in (C). Spearman's correlation coefficient and statistical significance (r- and p-values, respectively) were calculated with Prism 4 (GraphPad Software, Inc).

Findings reported here demonstrate the pathogenic potential of SHIV-1157ipd3N4 infection in pig-tailed macaques. The differential clinical responses in J02185, K03135, and L03165 (Figs. 1A, C, and 4A) suggest a spectrum of disease courses is possible from SHIV-C infections, consistent with previous findings in SIV and R5 SHIV strains, and the outbred nature of the animals studied. Peripheral lymphopenia and AIDS-defining events have also been documented in an Indian rhesus infected

with SHIV-1157ipd, a late-stage biological isolate from which SHIV-1157ipd3N4 was directly derived [58,59]. Additionally, long-term monitoring of SHIV-1157ipd3N4 infection in rhesus has shown AIDS progression in two animals (Chenine et al., unpublished data). Song et al. reported relatively stable absolute peripheral CD4<sup>+</sup> T-cell counts in all Indian- and Chinese-origin rhesus acutely infected with SHIV-1157ipd3N4 and followed for 12 weeks [58]. They also found that 43–66% of peripheral

CD4<sup>+</sup>T<sub>CM</sub> was depleted in two of five Indian rhesus at 8 weeks p.i. Compared to pre-existing levels at week 0, we found a similar 39–59% decrease of peripheral CD4<sup>+</sup>T<sub>CM</sub> in pig-tails at 2 weeks p.i.; by 8 weeks p.i., this decrease was 5–28%, reflecting the partial recovery of these cells in blood (data not shown). Interestingly, we observed an association between low pre-inoculation counts of peripheral CD4<sup>+</sup>T<sub>CM</sub> and progression to SHIV-C-induced disease in one animal (K03135) (data not shown), consistent with previous findings in SIVmac251-infected pig-tailed macaques [70]. Rhesus monkeys infected with another pathogenic R5 SHIV-C, SHIV-2873Nip, which was constructed from the backbone of SHIV-1157ipd3N4, also demonstrated a loss of peripheral CD4<sup>+</sup> memory T cells, along with depletion of gut CD4<sup>+</sup> T lymphocytes [71].

#### **Antibody-mediated immune responses to SHIV-1157ipd3N4 infection**

All three animals that were followed beyond the acute phase of SHIV-1157ipd3N4 infection were monitored for their antigen-specific antibody responses. As shown in Fig. 6, SIV-specific (Fig. 6A) and HIV-1 gp120-specific antibodies (Fig. 6B) were detected as early as 4 wk p.i. The antibody titers continued to increase for the following 6–8 months and persisted throughout the study period of a year, including animal K03135 that showed significant peripheral blood CD4<sup>+</sup> T-cell depletion after wk 24 p.i. (Fig. 4A), as well as animal J02185 that controlled virus replication after the acute phase and showed the lowest antibody response (Fig. 1A).

Neutralizing antibody (NtAb) activity was determined by the pseudotyped virus assay in TZM-bl cells [72]. Cross-clade NtAb responses were detected as early as 24 weeks p.i. (data not shown) against both subtype A and B primary isolates (Table 1), consistent with a previous report of rhesus monkeys infected with SHIV-1157ip, the parental virus of SHIV-1157ipd3N4 [73]. Similar to antibody responses measured by ELISA, animals with high and persistent viral loads (K03135 and L03165) showed greater levels of NtAb activities, consistent with the role of antigen load driving antibody responses. It should be noted however that the neutralizing activities observed were effective only against primary viruses that were relatively easy to neutralize (Q461d1, SF162, and SS1196.1). No activity was detected against 89.6 and two viruses represented in the standard subtype B primary isolate panel (QH0692.42 and SC422661.8) [74]. No neutralization was observed against the homologous virus (data not shown) or a heterologous subtype C virus 1084i [75] (Table 1). This was in contrast to the high-titered neutralizing activity against both homologous and heterologous R5 SHIV-C isolates in rhesus macaques infected with the parental virus SHIV-1157ip [73]. Thus, the NtAb profile in

SHIV-1157ipd3N4-infected pig-tailed macaques does not conform to the paradigm that homologous NtAbs arise before cross-clade NtAbs. In fact, cross-subtype NtAbs at titers similar to that in pooled plasma from subtype C-infected humans were observed in K03165 and L03165 relatively early after infection (wk 24, data not shown; and Table 1). The basis for this difference in NtAb responses is not known; but, it is likely to be due to the accessibility of conserved NtAb targets in certain isolates, regardless of their subtype classifications [76].

#### **Conclusion**

Our prospective analysis of SHIV-1157ipd3N4-infected animals with emphasis on early acute infection demonstrates that R5 SHIV-C-induced pathogenesis in pig-tailed macaques parallel findings in CCR5-tropic SIV/SHIV rhesus models. Findings reported here support the value of pig-tailed macaques as a relevant animal model for the study of lentiviral pathogenesis and preclinical AIDS vaccines.

#### **Methods**

##### **Animals**


Four juvenile pig-tailed macaques (*M. nemestrina*), all negative for simian type D retrovirus by serology and polymerase chain reaction (PCR), were used in this study. Animals were inoculated intrarectally, and tissue samples were collected at specific timepoints pre- and post-inoculation for prospective monitoring of viral loads, T-cell subsets, blood chemistry, and antibody responses. General health of the animals, including body weight and temperature, was monitored by routine examinations. All animals were cared for in accordance with established National Institutes of Health guidelines, and the experimental procedures were performed with the approval of the Institutional Animal Care and Use Committee at the University of Washington.

##### **Virus stock**

The derivation of SHIV-1157ipd3N4 was described by Song et al. [58]. A rhesus PBMC-grown stock was used for this study. All animals received 1 ml of undiluted SHIV-1157ipd3N4 by an atraumatic intrarectal inoculation. The virus stock had a p27 concentration of 95 ng/ml and an in vitro infectivity as determined by 50% tissue culture infectious doses (TCID<sub>50</sub>) of 10<sup>6</sup> per ml as titrated in TZM-bl cells (R. Song, personal communication).

##### **Cell line**

TZM-bl cells (also called JC53-bl, clone 13) were contributed by John Kappes and Xiaoyun Wu and obtained from the National Institutes of Health (NIH) AIDS Reference Reagent Repository Program (catalog no. 8129) [77]. Cells were cultured in Dulbecco modified Eagle medium



**Figure 6**  
**Virus-specific antibody responses in pig-tailed macaques infected with SHIV-1157ipd3N4.** Macaque sera were collected at the indicated times following SHIV-C inoculation and analyzed by ELISA for antibody responses directed against SIVmac whole virus (A) or HIV-1<sub>SF162</sub> gp120 (B). Endpoint titers were defined as the reciprocal of the highest dilution that gave an optical absorbance value at least threefold higher than the average values obtained with SIV-negative macaque sera.

supplemented with 10% fetal bovine serum (FBS) and 2 mM glutamine.

#### Tissue collection and isolation of lymphocytes

Peripheral blood was drawn by venipuncture into EDTA or SST tubes for extraction of plasma and PBMC, or serum, respectively. BAL samples were obtained by laryngoscope-aided introduction of a 5 mm video bronchoscope through the mouth and into the trachea. Lavage with 3–5 separate 10-ml aliquots of sterile saline was performed by injecting the saline into a terminal bronchiole, after which the saline infusate was aspirated with continuous flow vacuum at approximately 90–100 mm Hg of negative pressure. For endoscope-guided pinch biopsies obtained from the duodenum or colon, an 8.9 mm diameter video gastroscopy (Karl Storz Veterinary Endoscopy, Goleta,

CA) was inserted as far as the distal duodenum/proximal jejunum (90–130 cm from the mouth), or into the descending/transverse colon (50–70 cm from the anus), respectively. A maximum of 23 pinch biopsies (about 1 mm<sup>3</sup>) was collected via the gastroscopy with sterile 2.0 mm biopsy forceps.

EDTA-treated blood was subjected to Lymphoprep (Ficoll) density gradient centrifugation for isolation of viable PBMC, or stained by a whole blood lysis technique as described below. BAL samples were centrifuged to pellet cells, but enrichment of lymphocytes was not performed. Biopsies were pooled from the duodenum or colon, treated with 5 mM EDTA and 60 U/ml collagenase, and isolated cells were enriched for lymphocytes by Percoll density gradient centrifugation, as previously described [40,42]. Viability of intestinal lymphocytes averaged 88 ± 4%, as determined by trypan blue exclusion.

#### Plasma and cell-associated viral loads

Viral load was assayed as previously described [72,78]. Briefly, viral RNA load in EDTA-anticoagulated, cell-free plasma was determined by real-time RT-PCR after reverse transcriptase reaction. Proviral cDNA load in total mononuclear cells from peripheral blood or duodenal biopsies was determined by real-time PCR analysis.

#### Lymphocyte immunophenotyping

Cells were stained for four-color flow cytometric analysis, using antibodies directly conjugated to either fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll protein (PerCP), or allophycocyanin (APC). Briefly, for whole blood staining, 1 ml of whole blood was treated with 14 ml of ammonium chloride lysis solution for 7 min, centrifuged (700 × g, 5 min), and the resultant cell pellet was resuspended in 1 ml of staining medium (RPMI supplemented with 1% FBS and 0.02% NaN<sub>3</sub>) [72]. Fifty- $\mu$ l aliquots of the cell suspension were triple-stained with CD3-FITC (SP34-2), CD4-PerCP-Cy5.5 (L200), and CD8-APC (SK1), and double-stained with CD2-FITC (S5.2) and CD20-PerCP-Cy5.5 (L27). Cells were incubated in the dark for 20 to 30 min, washed, and resuspended in 1% paraformaldehyde. For mucosal and peripheral blood lymphocytes, cells were stained by incubating 1–5 × 10<sup>5</sup> cells with combinations of monoclonal antibodies at 4°C for 30 min, washed, and then fixed in 2% paraformaldehyde. Monoclonal antibodies used were: CD3-FITC (SP34), CD3-PerCP (SP34-2), CD4-APC (L200), CD8-PerCP (SK1), CD8-APC (SK1), CCR5-PE (3A9), CD28-PE (CD28.2), and CD95-FITC (DX2). All antibodies were purchased from Becton Dickinson Biosciences (San Jose, CA). Controls included appropriate unstained, fluorescence-minus-one (FMO)-stained, and single-color-stained, samples, for compensation and gat-

**Table 1: Serum neutralizing antibody response in pig-tailed macaques 36 weeks post-inoculation with SHIV-1157ipd3N4.**

Sample	Q461d1 (A) <sup>a</sup>	SF162 (B)	SS1196.1 (B)	89.6 (B)	QH0692.42(B)	SC422661.8 (B)	1084i (C)
J02185	<30 <sup>b</sup>	67	<30	<30	<30	<30	<30
K03135	2,338	3,369	309	<30	<30	<30	<30
L03165	1,009	2,430	221	<30	<30	<30	<30
Clade C Human	3,060	2,795	791	743	371	NT <sup>c</sup>	812

<sup>a</sup> Subtype of the indicator viruses.

<sup>b</sup> Neutralization titers are reported as IC<sub>50</sub>, or the highest serum dilution at which infectivity of the indicator viruses, as measured by relative luciferase units in the TZM-bl cell assay, was reduced by 50%.

<sup>c</sup> Not tested.

ing. Data were acquired on a FACSCalibur flow cytometer (Becton Dickinson Immunocytometry Systems), where 10,000–20,000 gated lymphocyte events were collected, and analyzed with FlowJo software (Version 7.1.3, Tree Star, Ashland, OR). The absolute numbers of CD3<sup>+</sup>CD4<sup>+</sup> lymphocytes were determined using flow cytometry analysis software according to guidelines from the Centers for Disease Control and Prevention for T-cell determinations in HIV-infected individuals [72].

#### Enzyme-linked immunosorbent assay (ELISA)

The titers of whole virus SIVmac- and HIV-1<sub>SF162</sub> gp120-specific antibodies were measured by ELISA as previously described [79]. Endpoint titers were determined as the reciprocal of the highest serum dilution that resulted in an optical density reading greater than the average values obtained with negative macaque sera plus three standard deviations.

#### Neutralization assay

The neutralization activity of sera from SHIV-1157ipd3N4-inoculated pig-tailed macaques was measured in a pseudotyped virus assay as described [72]. Indicator viruses with envelope derived from the following HIV-1 were used: subtype A isolate Q461d1 [80]; subtype B isolates SF162, SS1196.1, 89.6, QH0692.42, and SC422661.8 [72,74]; and subtype C isolate 1084i [75]. All assay stocks were titrated in TZM-bl cells as described previously [72,74]. Indicator virus containing 150 TCID<sub>50</sub> was incubated with serial dilutions of serum samples (starting at 1:30) in triplicate in a total volume of 60 µl for 1.5 hr at 37°C in 96-well U-bottom tissue culture plates (Corning). TZM-bl cells plated 24 hr previously (3,000 cells in 100 µl of growth medium) were treated with 2 µg/ml polybrene for 30 min at 37°C. One set of control wells received cells plus virus (virus control), and another set received cells only (background control). After a 72-hr incubation, luciferase activities were analyzed using BrightGlo substrate solution as described by the supplier (Promega). Neutralization activity was expressed as the

highest serum dilution that resulted in 50% reduction of relative luciferase units (RLU). Values obtained with pre-inoculation sera were subtracted from those obtained with post-inoculation sera for each animal.

#### Competing interests

The authors declare that they have no competing interests.

#### Authors' contributions

OH, KL, RMR, RS, and SLH designed the study. RMR and RS provided the SHIV-1157ipd3N4 virus stock. DA and SLH established funding for the study. KL coordinated and performed the primate studies. OH performed sample processing and immunophenotyping experiments. PP coordinated the viral load and ELISA experiments. YL performed the neutralization experiments. OH, PP, YL, and SLH analyzed the data, and OH and SLH wrote the manuscript. All authors read and approved the manuscript.

#### Acknowledgements

We thank the veterinary and animal care staff at the WaNPRC for excellent care of the macaques; Drs. Steve Kelley and Keith Vogel, and Leon Flanary and Joel Ahrens for mucosal sample collections; Dr. Robert Murnane for histopathological analyses; Heather Mack, Ryan Wallerstedt, Valerie Teske, Xuebing Li, Taryn Urion, and Modou Mbowe for expert technical assistance; and Drs. Don Sodora, Ron Veazey, Louis Picker, and John Fanton, and Kiran Mir and Amanda Leone for helpful discussions. This study is supported in part by NIH grants and contracts P51 RR0166 (WaNPRC) and P01 AI24048 (RMR and SLH).

#### References

- Batten CJ, De Rose R, Wilson KM, Agy MB, Chea S, Stratov I, Montefiori DC, Kent SJ: **Comparative evaluation of simian, simian-human, and human immunodeficiency virus infections in the pigtail macaque (*Macaca nemestrina*) model.** *AIDS Res Hum Retroviruses* 2006, **22**:580-588.
- Dewhurst S, Embretson JE, Anderson DC, Mullins JI, Fultz PN: **Sequence analysis and acute pathogenicity of molecularly cloned SIV<sub>SMM-PBj14</sub>.** *Nature* 1990, **345**:636-640.
- Haigwood NL: **Predictive values of primate models for AIDS.** *AIDS Rev* 2004, **6**:187-198.
- Hu S-L: **Non-human primate models for AIDS vaccine research.** *Curr Drug Targets Infect Disord* 2005, **5**:193-201.
- Israel ZR, Dean GA, Maul DH, O'Neil SP, Dreitz MJ, Mullins JI, Fultz PN, Hoover EA: **Early pathogenesis of disease caused by**

- SIV<sub>smmPBj14</sub> molecular clone I.9 in macaques.** *AIDS Res Hum Retroviruses* 1993, **9**:277-286.
6. Joag SV, Li Z, Foresman L, Stephens EB, Zhao LJ, Adany I, Pinson DM, McClure HM, Narayan O: **Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques.** *J Virol* 1996, **70**:3189-3197.
  7. Lackner AA, Veazey RS: **Current concepts in AIDS pathogenesis: insights from the SIV/macaque model.** *Annu Rev Med* 2007, **58**:461-476.
  8. Lifson JD, Nowak MA, Goldstein S, Rossio JL, Kinter A, Vasquez G, Wiltout TA, Brown C, Schneider D, Wahl L, Lloyd AL, Williams J, Elkins WR, Fauci AS, Hirsch VM: **The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection.** *J Virol* 1997, **71**:9508-9514.
  9. Novembre FJ, De Rosayro J, O'Neil SP, Anderson DC, Klumpp SA, McClure HM: **Isolation and characterization of a neuropathogenic simian immunodeficiency virus derived from a sooty mangabey.** *J Virol* 1998, **72**:8841-8851.
  10. Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, Willey R, Cho MW, Martin MA: **Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.** *Nat Med* 1999, **5**:204-210.
  11. Staprans SI, Feinberg MB: **The roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines.** *Expert Rev Vaccines* 2004, **3**:S5-32.
  12. Reimann KA, Li JT, Voss G, Lekutis C, Tenner-Racz K, Racz P, Lin W, Montefiori DC, Lee-Parritz DE, Lu Y, Collman RG, Sodroski J, Letvin NL: **An env gene derived from a primary human immunodeficiency virus type I isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys.** *J Virol* 1996, **70**:3198-3206.
  13. ten Haaf P, Almond N, Biberfeld G, Cafaro A, Cranage M, Ensoli B, Hunsmann G, Polyanskaya N, Stahl-Hennig C, Thortensson R, Titti F, Heeney J: **Comparison of early plasma RNA loads in different macaque species and the impact of different routes of exposure on SIV/SIV infection.** *J Med Primatol* 2001, **30**:207-214.
  14. Ling B, Veazey RS, Luckay A, Penedo C, Xu K, Lifson JD, Marx PA: **SIV(mac) pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans.** *AIDS* 2002, **16**:1489-1496.
  15. Burdo TH, Marcondes MC, Lanigan CM, Penedo MC, Fox HS: **Susceptibility of Chinese rhesus monkeys to SIV infection.** *AIDS* 2005, **19**:1704-1706.
  16. Fooden J: **Classification and distribution of living macaques.** In *The macaque: studies in ecology, behavior, and evolution* Edited by: Lindburg DG. New York: Van Nostrand-Reinhold; 1980:1-9.
  17. Tosi AJ, Morales JC, Melnick DJ: **Comparison of Y chromosome and mtDNA phylogenies leads to unique inferences of macaque evolutionary history.** *Mol Phylogenet Evol* 2000, **17**:133-144.
  18. Currier JR, Stevenson KS, Kehn PJ, Zheng K, Hirsch VM, Robinson MA: **Contributions of CD4+, CD8+, and CD4+CD8+ T cells to skewing within the peripheral T cell receptor beta chain repertoire of healthy macaques.** *Hum Immunol* 1999, **60**:209-222.
  19. Lafont BA, Buckler-White A, Plishka R, Buckler C, Martin MA: **Characterization of pig-tailed macaque classical MHC class I genes: implications for MHC evolution and antigen presentation in macaques.** *J Immunol* 2003, **171**:875-885.
  20. Brennan G, Kozyrev Y, Kodama T, Hu S-L: **Novel TRIM5 isoforms expressed by *Macaca nemestrina*.** *J Virol* 2007, **81**:12210-12217.
  21. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J: **The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.** *Nature* 2004, **427**:848-853.
  22. Agy MB, Frumkin LR, Corey L, Coombs RW, Wolinsky SM, Koehler J, Morton WR, Katze MG: **Infection of *Macaca nemestrina* by human immunodeficiency virus type-1.** *Science* 1992, **257**:103-106.
  23. Bosch ML, Schmidt A, Chen J, Florey MJ, Agy M, Morton WR: **Enhanced replication of HIV-1 in vivo in pigtailed macaques (*Macaca nemestrina*).** *J Med Primatol* 2000, **29**:107-113.
  24. Hatziioannou T, Ambrose Z, Chung NP, Piatak M Jr, Yuan F, Trubey CM, Coalter V, Kiser R, Schneider D, Smedley J, Pung R, Gathuka M, Estes JD, Veazey RS, KewalRamani VN, Lifson JD, Bieniasz PD: **A macaque model of HIV-1 infection.** *Proc Natl Acad Sci USA* 2009, **106**:4425-4429.
  25. Polacino P, Larsen K, Galmin L, Suschak J, Kraft Z, Stamatatos L, Anderson D, Barnett SW, Pal R, Bost K, Bandivdekar AH, Miller CJ, Hu S-L: **Differential pathogenicity of SHIV<sub>SF162P4</sub> infection in pig-tailed and rhesus macaques.** *J Med Primatol* 2008, **37**:13-23.
  26. Rosenberg YJ, White BD, Papermaster SF, Zack P, Jarling PB, Eddy GA, Burke DS, Lewis MG: **Variation in T-lymphocyte activation and susceptibility to SIVPBj-14-induced acute death in macaques.** *J Med Primatol* 1991, **20**:206-210.
  27. Kuller L, Schmidt A, Mack H, Durning M, Birkebak T, Reiner MT, Anderson DM, Morton WR, Agy MB: **Systemic and intestinal immune responses to HIV-2<sub>287</sub> infection in *Macaca nemestrina*.** *AIDS Res Hum Retroviruses* 2001, **17**:1191-1204.
  28. McClure J, Schmidt AM, Rey-Cuille MA, Bannink J, Misher L, Tsai CC, Anderson DM, Morton WR, Hu S-L: **Derivation and characterization of a highly pathogenic isolate of human immunodeficiency virus type 2 that causes rapid CD4+ cell depletion in *Macaca nemestrina*.** *J Med Primatol* 2000, **29**:114-126.
  29. Otten RA, Brown BG, Simon M, Lupo LD, Parekh BS, Lairmore MD, Schable CA, Schochetman G, Rayfield MA: **Differential replication and pathogenic effects of HIV-1 and HIV-2 in *Macaca nemestrina*.** *AIDS* 1994, **8**:297-306.
  30. Picker LJ: **Immunopathogenesis of acute AIDS virus infection.** *Curr Opin Immunol* 2006, **18**:399-405.
  31. Veazey RS, Marx PA, Lackner AA: **The mucosal immune system: primary target for HIV infection and AIDS.** *Trends Immunol* 2001, **22**:626-633.
  32. Douek DC, Picker LJ, Koup RA: **T cell dynamics in HIV-1 infection.** *Annu Rev Immunol* 2003, **21**:265-304.
  33. Kewenig S, Schneider T, Hohloch K, Lampe-Dreyer K, Ullrich R, Stolte N, Stahl-Hennig C, Kaup FJ, Stallmach A, Zeitz M: **Rapid mucosal CD4+ T-cell depletion and enteropathy in simian immunodeficiency virus-infected rhesus macaques.** *Gastroenterology* 1999, **116**:1115-1123.
  34. Lifson JD, Piatak M Jr, Cline AN, Rossio JL, Purcell J, Pandrea I, Bischofberger N, Blanchard J, Veazey RS: **Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge.** *J Med Primatol* 2003, **32**:201-210.
  35. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M: **Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection.** *Nature* 2005, **434**:1093-1097.
  36. Pandrea IV, Gautam R, Ribeiro RM, Brenchley JM, Butler IF, Pattison M, Rasmussen T, Marx PA, Silvestri G, Lackner AA, Perelson AS, Douek DC, Veazey RS, Apetrei C: **Acute loss of intestinal CD4+ T cells is not predictive of simian immunodeficiency virus virulence.** *J Immunol* 2007, **179**:3035-3046.
  37. Picker LJ, Hagen SI, Lum R, Reed-Inderbitzin EF, Daly LM, Sylwester AW, Walker JM, Siess DC, Piatak M Jr, Wang C, Allison DB, Maino VC, Lifson JD, Kodama T, Axthelm MK: **Insufficient production and tissue delivery of CD4+ memory T cells in rapidly progressive simian immunodeficiency virus infection.** *J Exp Med* 2004, **200**:1299-1314.
  38. Smit-McBride Z, Mattapallil JJ, McChesney M, Ferrick D, Dandekar S: **Gastrointestinal T lymphocytes retain high potential for cytokine responses but have severe CD4+ T-cell depletion at all stages of simian immunodeficiency virus infection compared to peripheral lymphocytes.** *J Virol* 1998, **72**:6646-6656.
  39. Veazey RS, DeMaria M, Chalifoux LV, Shvets DE, Pauley DR, Knight HL, Rosenzweig M, Johnson RP, Desrosiers RC, Lackner AA: **Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection.** *Science* 1998, **280**:427-431.
  40. Veazey RS, Mansfield KG, Tham IC, Carville AC, Shvets DE, Forand AE, Lackner AA: **Dynamics of CCR5 expression by CD4+ T cells in lymphoid tissues during simian immunodeficiency virus infection.** *J Virol* 2000, **74**:11001-11007.
  41. Veazey RS, Marx PA, Lackner AA: **Vaginal CD4+ T cells express high levels of CCR5 and are rapidly depleted in simian immunodeficiency virus infection.** *J Infect Dis* 2003, **187**:769-776.
  42. Veazey RS, Tham IC, Mansfield KG, DeMaria M, Forand AE, Shvets DE, Chalifoux LV, Sehgal PK, Lackner AA: **Identifying the target cell in primary simian immunodeficiency virus (SIV) infec-**

- tion: highly activated memory CD4+ T cells are rapidly eliminated in early SIV infection in vivo.** *J Virol* 2000, **74**:57-64.
43. Ling B, Veazey RS, Hart M, Lackner AA, Kuroda M, Pahar B, Marx PA: **Early restoration of mucosal CD4 memory CCR5 T cells in the gut of SIV-infected rhesus predicts long term non-progression.** *AIDS* 2007, **21**:2377-2385.
  44. Pahar B, Lackner AA, Piatak M Jr, Lifson JD, Wang X, Das A, Ling B, Montefiori DC, Veazey RS: **Control of viremia and maintenance of intestinal CD4+ memory T cells in SHIV<sub>162P3</sub> infected macaques after pathogenic SIV<sub>MAC251</sub> challenge.** *Virology* 2009, **387**:273-84.
  45. Veazey RS, Acierio PM, McEvers KJ, Baumeister SH, Foster GJ, Rett MD, Newberg MH, Kuroda MJ, Williams K, Kim EY, Wolinsky SM, Rieber EP, Piatak M Jr, Lifson JD, Montefiori DC, Brown CR, Hirsch VM, Schmitz JE: **Increased loss of CCR5+ CD45RA- CD4+ T cells in CD8+ lymphocyte-depleted Simian immunodeficiency virus-infected rhesus monkeys.** *J Virol* 2008, **82**:5618-5630.
  46. Paiardini M, Frank I, Pandrea I, Apetrei C, Silvestri G: **Mucosal immune dysfunction in AIDS pathogenesis.** *AIDS Rev* 2008, **10**:36-46.
  47. Veazey R, Lackner A: **The mucosal immune system and HIV-1 infection.** *AIDS Rev* 2003, **5**:245-252.
  48. Mattapallil JJ, Letvin NL, Roederer M: **T-cell dynamics during acute SIV infection.** *AIDS* 2004, **18**:13-23.
  49. Harouse JM, Gettie A, Tan RC, Blanchard J, Cheng-Mayer C: **Distinct pathogenic sequelae in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs.** *Science* 1999, **284**:816-819.
  50. Nishimura Y, Igarashi T, Donau OK, Buckler-White A, Buckler C, Lafont BA, Goeken RM, Goldstein S, Hirsch VM, Martin MA: **Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses.** *Proc Natl Acad Sci USA* 2004, **101**:12324-12329.
  51. Vlasak J, Ruprecht RM: **AIDS vaccine development and challenge viruses: getting real.** *AIDS* 2006, **20**:2135-2140.
  52. Harouse JM, Gettie A, Eshetu T, Tan RC, Bohm R, Blanchard J, Baskin G, Cheng-Mayer C: **Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV<sub>SF162P3</sub>.** *J Virol* 2001, **75**:1990-1995.
  53. Luciw PA, Pratt-Lowe E, Shaw KE, Levy JA, Cheng-Mayer C: **Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV).** *Proc Natl Acad Sci USA* 1995, **92**:7490-7494.
  54. Pahar B, Wang X, Dufour J, Lackner AA, Veazey RS: **Virus-specific T cell responses in macaques acutely infected with SHIV(sf162p3).** *Virology* 2007, **363**:36-47.
  55. Pal R, Taylor B, Foulke JS, Woodward R, Merges M, Praschunus R, Gibson A, Reitz M: **Characterization of a simian human immunodeficiency virus encoding the envelope gene from the CCR5-tropic HIV-1 Ba-L.** *J Acquir Immune Defic Syndr* 2003, **33**:300-307.
  56. Tan RC, Harouse JM, Gettie A, Cheng-Mayer C: **In vivo adaptation of SHIV(SF162): chimeric virus expressing a NSI, CCR5-specific envelope protein.** *J Med Primatol* 1999, **28**:164-168.
  57. Tsai L, Trunova N, Gettie A, Mohri H, Bohm R, Saifuddin M, Cheng-Mayer C: **Efficient repeated low-dose intravaginal infection with X4 and R5 SHIVs in rhesus macaque: implications for HIV-1 transmission in humans.** *Virology* 2007, **362**:207-216.
  58. Song RJ, Chenine AL, Rasmussen RA, Ruprecht CR, Mirshahidi S, Grisson RD, Xu W, Whitney JB, Goins LM, Ong H, Li PL, Shai-Kobiler E, Wang T, McCann CM, Zhang H, Wood C, Kankasa C, Secor WE, McClure HM, Strobert E, Else JG, Ruprecht RM: **Molecularly cloned SHIV-1157ipd3N4: a highly replication-competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV-1 clade C env.** *J Virol* 2006, **80**:8729-8738.
  59. Humbert M, Rasmussen RA, Song R, Ong H, Sharma P, Chenine AL, Kramer VG, Siddappa NB, Xu W, Else JG, Novembre FJ, Strobert E, O'Neil SP, Ruprecht RM: **SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys.** *Retrovirology* 2008, **5**:94-105.
  60. Chen Z, Huang Y, Zhao X, Skulsky E, Lin D, Ip J, Gettie A, Ho DD: **Enhanced infectivity of an R5-tropic simian/human immunodeficiency virus carrying human immunodeficiency virus type I subtype C envelope after serial passages in pig-tailed macaques (Macaca nemestrina).** *J Virol* 2000, **74**:6501-6510.
  61. Chen Z, Zhao X, Huang Y, Gettie A, Ba L, Blanchard J, Ho DD: **CD4+ lymphocytopenia in acute infection of Asian macaques by a vaginally transmissible subtype-C, CCR5-tropic Simian/Human Immunodeficiency Virus (SHIV).** *J Acquir Immune Defic Syndr* 2002, **30**:133-145.
  62. Chase AJ, Sedaghat AR, German JR, Gama L, Zink MC, Clements JE, Siliciano RF: **Severe depletion of CD4+ CD25+ regulatory T cells from the intestinal lamina propria but not peripheral blood or lymph nodes during acute simian immunodeficiency virus infection.** *J Virol* 2007, **81**:12748-12757.
  63. Okoye A, Meier-Schellersheim M, Brenchley JM, Hagen SI, Walker JM, Rohankhedkar M, Lum R, Edgar JB, Planer SL, Legasse A, Sylwester AW, Piatak M Jr, Lifson JD, Maino VC, Sodora DL, Douek DC, Axthelm MK, Grossman Z, Picker LJ: **Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection.** *J Exp Med* 2007, **204**:2171-2185.
  64. Heise C, Vogel P, Miller CJ, Lackner A, Dandekar S: **Distribution of SIV infection in the gastrointestinal tract of rhesus macaques at early and terminal stages of disease.** *J Med Primatol* 1993, **22**:187-193.
  65. Li Q, Duan L, Estes JD, Ma ZM, Rourke T, Wang Y, Reilly C, Carlis J, Miller CJ, Haase AT: **Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells.** *Nature* 2005, **434**:1148-1152.
  66. Pandrea I, Apetrei C, Gordon S, Barbercheck J, Dufour J, Bohm R, Sumpter B, Roques P, Marx PA, Hirsch VM, Kaur A, Lackner AA, Veazey RS, Silvestri G: **Paucity of CD4+CCR5+ T cells is a typical feature of natural SIV hosts.** *Blood* 2007, **109**:1069-1076.
  67. Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, Kottitil S, Moir S, Mican JM, Mullins JI, Ward DJ, Kovacs JA, Mannon PJ, Fauci AS: **Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy.** *J Infect Dis* 2008, **197**:714-720.
  68. Poles MA, Boscardin WJ, Elliott J, Taing P, Fuerst MM, McGowan I, Brown S, Anton PA: **Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals.** *J Acquir Immune Defic Syndr* 2006, **43**:65-68.
  69. Shacklett BL, Critchfield JW, Ferre AL, Hayes TL: **Mucosal T-cell responses to HIV: responding at the front lines.** *J Intern Med* 2009, **265**:58-66.
  70. Mason RD, De Rose R, Seddiki N, Kelleher AD, Kent SJ: **Low pre-infection levels and loss of central memory CD4+ T cells may predict rapid progression in SIV-infected pigtail macaques.** *Virology* 2008, **381**:11-15.
  71. Siddappa NB, Song R, Kramer VG, Chenine AL, Velu V, Ong H, Rasmussen RA, Grisson RD, Wood C, Zhang H, Kankasa C, Amara RR, Else JG, Novembre FJ, Montefiori DC, Ruprecht RM: **Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection.** *J Virol* 2009, **83**:1422-32.
  72. Li Y, Cleveland B, Klots I, Travis B, Richardson BA, Anderson D, Montefiori D, Polacino P, Hu S-L: **Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.** *J Virol* 2008, **82**:638-651.
  73. Humbert M, Rasmussen RA, Ong H, Kaiser FM, Hu SL, Ruprecht RM: **Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing.** *PLoS ONE* 2008, **3**:e3937.
  74. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Biliska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC: **Human immunodeficiency virus type I env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.** *J Virol* 2005, **79**:10108-10125.
  75. Grisson RD, Chenine AL, Yeh LY, He J, Wood C, Bhat GJ, Xu W, Kankasa C, Ruprecht RM: **Infectious molecular clone of a recently transmitted pediatric human immunodeficiency virus clade C isolate from Africa: evidence of intraclade recombination.** *J Virol* 2004, **78**:14066-14069.
  76. Kraft Z, Strouss K, Sutton WF, Cleveland B, Tso FY, Polacino P, Overbaugh J, Hu SL, Stamatatos L: **Characterization of neutralizing antibody responses elicited by clade A envelope immu-**

- nogens derived from early transmitted viruses. *J Virol* 2008, **82**:5912-5921.
77. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC: **Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.** *Agents Chemother* 2002, **46**:1896-1905.
  78. Polacino P, Cleveland B, Zhu Y, Kimata JT, Overbaugh J, Anderson D, Hu SL: **Immunogenicity and protective efficacy of Gag/Pol/Env vaccines derived from temporal isolates of SIVmne against cognate virus challenge.** *J Med Primatol* 2007, **36**:254-65.
  79. Hu SL, Zarlring JM, Chinn J, Travis BM, Moran PA, Sias J, Kuller L, Morton WR, Heidecker G, Benveniste RE: **Protection of macaques against simian AIDS by immunization with a recombinant vaccinia virus expressing the envelope glycoproteins of simian type D retrovirus.** *Proc Natl Acad Sci USA* 1989, **86**:7213-7217.
  80. Blish CA, Nedellec R, Mandaliya K, Mosier DE, Overbaugh J: **HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.** *AIDS* 2007, **21**:693-702.

Publish with **BioMed Central** and every scientist can read your work free of charge

*"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."*

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

